News & Media

Completion of sale of VelosBio

Artios and Merck KGaA announce global strategic collaboration

VelosBio to be acquired by Merck for $2.75 billion

Arix to present at Proactive One2One Biotech Forum

Arix announces strategic and operational update

Arix to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Amplyx closes $53 million Series C extension

Notice of Annual General Meeting

Investment team changes

Imara prices Nasdaq IPO

Arix names Dr Roberto Iacone as Entrepreneur in Residence

Arix co-founds Quench Bio with Series A financing

Iterum announces $52 million private placement

Arix 2019 Capital Markets Day

Arix co-leads EUR 20 million Series A investment round in STipe Therapeutics

Imara announces confidential submission of draft registration statement for proposed US IPO

Interim results for the six months ended 30 June 2019

Arix Bioscience plc Autolus announces closing of public offering

Autolus announces pricing of public offering

Aura completes $40 million Series D financing

Annual Results for the year ended 31 December 2018

Arix Bioscience plc Board changes

Arix co-leads $63 million Series B investment round for Imara

Management and Board changes

Harpoon closes initial public offering

Harpoon prices Nasdaq IPO

Update on Harpoon proposed IPO in the United States

Harpoon announces proposed public offering in the United States

Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)

Autolus presents initial AUTO3 data at ASH

Update on LogicBio proposed initial public offering in the United States

Co-leads $58 million Series A investment round for VelosBio

LogicBio files registration for proposed IPO in the US

Arix Bioscience Plc announces Board changes

Changes announced to executive team to accelerate growth and strategy

Artios completes £65m Series B investment round

Arix Bioscience announces first VIPE investment

Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018

Autolus announces closing of IPO

Update on Autolus proposed initial public offering in the United States

Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

Iterum Therapeutics plc Closes Initial Public Offering

Iterum Therapeutics plc Prices Initial Public Offering

Annual Results 2017

Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018

Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients

Arix Bioscience co-leads $30 million financing for Aura Biosciences

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Arix Bioscience leads $65 million Series B investment round for Iterum

Maiden Annual Results 2016

Arix supports Artios Pharma, a new biotech company focused on DNA damage response

ARIX BIOSCIENCE SUPPORTS DEPIXUS, AN EARLY-STAGE COMPANY FOCUSED ON NUCLEIC ACID SEQUENCING & EPIGENETIC ANALYSIS

ARIX BIOSCIENCE SUPPORTS INNOVATIVE RESPIRATORY DRUG COMPANY VERONA PHARMA PLC

ARIX BIOSCIENCE SUPPORTS OPTIKIRA, A COMPANY DEVELOPING DRUGS TO FIGHT BLINDNESS

ARIX BIOSCIENCE HAS MADE $25 MILLION COMMITMENT TO LEADING THERAPEUTICS RESEARCH ACCELERATOR, BIOMOTIV

ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS